Facebook
Twitter
LinkedIn
WhatsApp

Stage 4 Cancer

Stage 4, Stage IV metastatic cancer

“Metastases cancer” or stage 4 cancer, is the medical term for describing a condition where a tumor originating in a certain organ, “primary tumor”, is identified in another organ or in a distant location from the original organ, e.g., metastases of breast cancer can be found in the lungs, brain, bones and liver.

It is important to note, metastases are the same type of the original primary tumor, even if its location is in distant organs and so are the treatments regarded as such, for example, a treatment for a metastatic lung cancer that has spread to the liver, is determined by the treatment for metastatic lung cancer and not by the treatment for liver cancer.

Metastases formation

Cancer cells of the primary tumor can be released into the bloodstream and lymphatic system and circulate to distant organs or adjacent organs and tissues to the primary tumor and “settle” in them and grow.

There are different types of cancer which is known where metastases can be formed, for example,

  • Breast cancer can spread to the bones, brain, liver and lungs
  • Lung cancer can spread to the brain, bones, liver and kidney
  • Prostate cancer can spread to the bones
  • Colon cancer, rectal cancer, colorectal cancer can spread to the liver and lungs
Breast cancer can spread to the bones, brain, liver and lungs
Breast cancer can spread to the bones, brain, liver and lungs

Stage IV metastatic cancer and recovery

In the vast majority of the metastatic cases, the treatments do not cure. Treatment goals are slowing tumor growth rate, prolonging life and reducing the symptoms of the disease, improving the quality of life of the patient.

The efficacy of the treatments is affected by many factors, among them are the type of cancer, number of metastases (also called “lesions”) and their location, how much cancer the patient has in his or her body, growth rate of the tumor lesions, medical history of the patient, background diseases, microenvironment between the tumor cells themselves, resistance the tumor has developed to previous treatments and other.

Advanced treatments and clinical trials for stage 4

The National Cancer Institute (NCI) highlights the fact that for a certain group of metastatic cancer patients, the best treatment option is to join one of the many clinical trials existing worldwide aiming to increase their chances of therapeutic success.

This is also recommended by the USA national comprehensive cancer network, NCCN,  (USA national comprehensive cancer network)

“Patients with cancer should be encouraged to participate in clinical trials during all aspects of their diagnosis and treatment”

Currently, every patient will be offered the standard protocols described above. Sometimes the oncologist may suggest integrating these therapies with trials carried out in the Institute.

Advances in cancer therapies may be found in clinical trials prescribing cutting edge, interesting drugs, some of which have already been recognized by the FDA (US Food & Drug Administration) as “breakthrough treatments” and require further information input before being finally and fully approved.

An entire world of clinical trials and compassionate drugs and treatments are open and available worldwide. It is important to know which cutting edge treatments exist which patients can gain far more from them than the standard care offered.

For most patients with stage 4 metastatic cancer, current treatments are insufficiently effective. This gives rise to the need for innovative strategies with greater efficacy in fighting the disease.

Read our publications on innovative treatments for stage 4 metastatic cancer:

To check if our service suits your case
We need to talk

Improve therapeutic outcomes, prolong life and quality of life, is our main business.
We support access to and expand cancer treatments beyond the standard of care, with the most advanced and innovative treatment options in the world, personally matching the individual cancer patient’s medical condition and with the support of top tier oncologists.

Article categories

קטגוריות המאמרים

Popular topics

Facebook
Twitter
LinkedIn
WhatsApp

Chondrosarcoma – Ivosidenib works in Chondrosarcoma

Chondrosarcoma and IDH1 – Background

For locally advanced and/or metastatic Chondrosarcoma, no known effective therapy exists. The standard protocols are not effective. Mutations in the IDH1/2 enzymes occur in up to 65% of Chondrosarcoma cases. Ivosidenib (AG-120) is a selective inhibitor of mutant IDH1 approved in the United States for specific cases of acute myeloid leukemia. An ongoing study evaluating Ivosidenib treatment in patients with advanced Chondrosarcoma reported outcomes.

About the study

It is a phase I multicenter study of Ivosidenib monotherapy which enrolled patients with mutant IDH1 advanced solid tumors, including Chondrosarcoma. Ivosidenib was administered orally (100 mg twice daily to 1,200 mg once daily) in continuous 28-day cycles.

Results and Side effects

21 patients with advanced Chondrosarcoma received Ivosidenib.

  • Stable disease was achieved in 52% of patients.
  • The median time until disease progression under the treatment was 5.6 months.
  • In 39.5% of patients, the disease had not progressed after 6 months of treatment.
  • 4 patients received treatment for ≥2.5 years without progressive disease.
  • Results were inferior in dedifferentiated tumors.

Treatment-related side effects were mostly very mild. 12 patients experienced serious side effects; only one event was judged treatment related (hypophosphatemia).

Conclusion

  • In patients with Chondrosarcoma, Ivosidenib showed minimal toxicity and durable disease control.
  • Phase I clinical trials are attractive to cancer patients and should be considered as treatment options.
  • The best treatment for a cancer patient is to get the most advanced cancer drugs in advanced stages of development. There, the hope and the chance to extend life go far beyond the standard protocols.

Contact us to find out what is the best treatment for YOU

TRIAL•IN Pharma

Because we, do not give up on life!

Contact us 24/7 –

Call center +44.2082.426.039

For further reading>>

To read about Clinical Trials>>

Chondrosarcoma News
Chondrosarcoma News

What is Sarcoma?

Sarcoma is a name for skeletal and soft tissue tumors. These tumors include over 70 cancer subtypes. These tumors develop from bones, cartilage and soft tissues such as connective tissue, muscle, fat, blood vessels and nerves. Bone sarcomas are usually separated from soft tissue sarcomas. Bone origin sarcoma accounts for about 20% of tumors, and is characterized by a number of different subtypes, most commonly called “Osteosarcoma.” Soft tissue sarcomas make up 80% of all sarcomas, and have about 60 different subtypes. The most common soft tissue sarcomas are “Leiomyosarcoma”, “Liposarcoma” and “Pleomorphic sarcoma”.

No Cost service compatibility check
Please fill in the details and we will back to you as soon as possible

Improving therapeutic success, extending life and quality of life are our main business. We extend to metastatic cancer patients and patients with brain tumors, the most advanced treatment options in the world and the best experts in Israel and abroad.

Article categories

קטגוריות המאמרים

Popular topics